Stock Analiz

Vivos Therapeutics, Inc. VVOS

Medical/Dental Instruments · IPO 2020 · data as of November 13, 2026

$0.10Market cap $3M
Open the interactive analysis →

Vivos Therapeutics, Inc. (VVOS) is a healthcare company listed in the US with a market value of about $3M. In the twelve months to June 30, 2026 it had revenue of $21M and net income of -$25M, a net margin of -121.8%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 6% a year, a 5-year average ROIC of -186%.

About Vivos Therapeutics

Vivos Therapeutics is listed in the US and classified in medical/dental instruments, IPO year 2020. Revenue went from $11M in 2019 to $17M in 2025, growth of about 7.4% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 1016% over three years (dilution for shareholders). It spends 1% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health0/5
Shareholder returns1/5

Checks passed

  • Revenue growth above 10% last year
  • ROE above 15%
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.2
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-577.2%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)16.1%
Revenue growth (5 yrs, per year)5.9%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-112.6%
ROIC (5-yr avg.)-185.5%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$21M$17M$15M$14M$16M$17M$13M$11M
Net income-$25M-$21M-$11M-$14M-$24M-$20M-$12M-$11M
Free cash flow-$19M-$18M-$13M-$13M-$21M-$18M-$6M-$6M
EPS (diluted)$-1.90$-2.07$-2.22$-11.14$-25.90$-23997.20$-34995.92$-23747.23
Net margin-121.8%-121.4%-74.1%-98.4%-148.8%-120.2%-92.3%-94.4%
ROIC—-132.7%-82.7%-378.9%-274.1%-59.3%-52.2%-1090.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Vivos Therapeutics pay a dividend?

Not currently.

Is Vivos Therapeutics a good stock to buy?

We do not give buy or sell advice. Vivos Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.